Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous cervical cancer-specific engineered immune effector cells

A preparation of autologous immune effector cells genetically modified to target a not yet disclosed cervical cancer-specific tumor-associated antigen (TAA), with potential immunomodulating and antineoplastic activities. After isolation, transduction, expansion in culture, and reintroduction into the patient, the autologous cervical cancer-specific engineered immune effector (CC-EIE) cells bind to and induce selective toxicity in tumor cells expressing the TAA.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	autologous CC-EIE cells autologous CC-EIEs

autologous cervical cancer-specific engineered immune effector cells

Search NCI's Drug Dictionary